180 Wealth Advisors, LLC Biomarin Pharmaceutical Inc Transaction History

180 Wealth Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 16, 2024	SELL	$74.43 - $92.22 $4,465 - $5,533	-60 Reduced 2.07%	2,833 $233,000
Q1 2024 Apr 15, 2024	SELL	$83.81 - $99.0 $11,481 - $13,563	-137 Reduced 4.52%	2,893 $252,000
Q4 2023 Jan 24, 2024	SELL	$76.22 - $98.51 $14,253 - $18,421	-187 Reduced 5.81%	3,030 $292,000
Q3 2023 Oct 31, 2023	BUY	$85.07 - $94.48 $18,885 - $20,974	222 Added 7.41%	3,217 $284,000
Q2 2023 Jul 11, 2023	BUY	$86.68 - $100.3 $8,494 - $9,829	98 Added 3.38%	2,995 $259,000
Q1 2023 Apr 07, 2023	BUY	$87.74 - $117.27 $254,182 - $339,731	2,897 New	2,897 $281,000
Q4 2021 Jan 26, 2022	SELL	$71.72 - $91.47 $390,874 - $498,511	-5,450 Closed	0 $0
Q3 2021 Oct 28, 2021	BUY	$74.77 - $85.47 $33,496 - $38,290	448 Added 8.96%	5,450 $414,000
Q2 2021 Aug 13, 2021	BUY	$75.51 - $84.79 $87,365 - $98,102	1,157 Added 30.09%	5,002 $385,000
Q1 2021 May 25, 2021	BUY	$74.73 - $90.69 $287,336 - $348,703	3,845 New	3,845 $300,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of 180 Wealth Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on 180 Wealth Advisors, LLC with notifications on news.